Table 3:

Cumulative incidence of CKE and MACE according to UACR categories.

	CKE, %				MACE, %
UACR categories BSL	≥0–<0.1 g/g	≥0.1–<0.6 g/g	≥0.6–<1.4 g/g	≥1.4 g/g	≥0–<0.1 g/g	≥0.1–<0.6 g/g	≥0.6–<1.4 g/g	≥1.4 g/g
FU2	4.77	10.10	17.93	26.64	2.12	2.42	2.35	1.78
FU4	9.65	19.83	33.66	47.44	5.04	5.72	5.57	4.23
FU6	11.25	22.89	38.29	53.07	5.04	5.72	5.57	4.23

BSL: baseline; FU2: follow-up at 2 years; FU4: follow-up at 4 years; FU6: follow-up at 6 years.

The percentages indicate the proportion of patients within each UACR category who experienced CKE or MACE during the specified follow-up periods.